Cerulean Appoints Vice President, Regulatory Affairs

CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Pamela Strode as Vice President, Regulatory Affairs.

"Pam has extensive regulatory and oncology experience across all phases of product development, from pre-clinical through the post marketing life-cycle, as well as strategic expertise that will help Cerulean advance its nanoparticle-drug conjugates, or NDCs, through the clinic to commercialization," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

Strode will oversee all facets of Cerulean's regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities.

Ms. Strode joins Cerulean from Boehringer Ingelheim Pharmaceuticals, Inc., where she spent approximately 20 years in positions of increasing responsibility in drug regulatory affairs, most recently as Executive Director. Prior to Boehringer Ingelheim, Ms. Strode worked in regulatory affairs for 6 years at Bristol-Myers Squibb and previously worked in research and development there and at Hoffmann-La Roche. Ms. Strode received a B.S. in Microbiology from Cook College at Rutgers University and a M.S. in Quality Assurance and Regulatory Affairs from Temple University.

"Cerulean's NDCs are intriguing to me because they are designed to specifically target tumor cells, spare normal tissue, and most importantly to enable unique combinations," said Ms. Strode. "My new role provides an opportunity to immediately leverage my experience to help advance the three combination trials evaluating CRLX-101 and to help usher CRLX-301 into the clinic."

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.


Contact Data